Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
11 2020
Historique:
received: 14 03 2020
revised: 25 05 2020
accepted: 25 06 2020
pubmed: 24 7 2020
medline: 15 12 2020
entrez: 24 7 2020
Statut: ppublish

Résumé

Macrophage activation by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals mediates an interleukin (IL)-1β-dependent inflammation during gout and pseudo-gout flare, respectively. Since metabolic reprogramming of macrophages goes along with inflammatory responses dependently on stimuli and tissue environment, we aimed to decipher the role of glycolysis and oxidative phosphorylation in the IL-1β-induced microcrystal response. Briefly, an in vitro study (metabolomics and real-time extracellular flux analysis) on MSU and CPP crystal-stimulated macrophages was performed to demonstrate the metabolic phenotype of macrophages. Then, the role of aerobic glycolysis in IL-1β production was evaluated, as well in vitro as in vivo using We observed that MSU and CPP crystals led to a metabolic rewiring toward the aerobic glycolysis pathway explained by an increase in GLUT1 plasma membrane expression and glucose uptake on macrophages. Also, neutrophils isolated from human synovial fluid during gout flare expressed GLUT1 at their plasma membrane more frequently than neutrophils isolated from bloodstream. Both glucose deprivation and treatment with either 2-deoxyglucose or GLUT1 inhibitor suppressed crystal-induced NLRP3 activation and IL-1β production, and microcrystal inflammation in vivo. In conclusion, we demonstrated that GLUT1-mediated glucose uptake is instrumental during the inflammatory IL-1β response induced by MSU and CPP crystals. These findings open new therapeutic paths to modulate crystal-related inflammation.

Identifiants

pubmed: 32699039
pii: annrheumdis-2020-217342
doi: 10.1136/annrheumdis-2020-217342
doi:

Substances chimiques

Glucose Transporter Type 1 0
Interleukin-1beta 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
Uric Acid 268B43MJ25
Calcium Pyrophosphate X69NU20D19

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1506-1514

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Felix Renaudin (F)

Universite de Paris, Paris, France.
INSERM, UMR-S 1132, F-75010, Paris, France.

Lucie Orliaguet (L)

Universite de Paris, Paris, France.
INSERM, Immunity and Metabolism in Diabetes Laboratory, Centre de Recherche des Cordelier, Paris, France.

Florence Castelli (F)

Service de Pharmacologie et immunoanalyse (SPI), Laboratoire d'Etude du Métabolisme des Médicaments, CEA, INRAE, Université Paris Saclay, Gif-Sur-Yvette, France.

François Fenaille (F)

Service de Pharmacologie et immunoanalyse (SPI), Laboratoire d'Etude du Métabolisme des Médicaments, CEA, INRAE, Université Paris Saclay, Gif-Sur-Yvette, France.

Aurelie Prignon (A)

UMS28 Phénotypage du Petit Animal, Laboratoire d'Imagerie Moléculaire Positonique (LIMP), F-75020, Sorbonne Université, Paris, France.

Fawaz Alzaid (F)

Universite de Paris, Paris, France.
INSERM, Immunity and Metabolism in Diabetes Laboratory, Centre de Recherche des Cordelier, Paris, France.

Christele Combes (C)

UMR 5085 INPT-UPS-CNRS, Université de Toulouse, ENSIACET, F-31000, Toulouse, France.

Aurélie Delvaux (A)

Service de Pharmacologie et immunoanalyse (SPI), Laboratoire d'Etude du Métabolisme des Médicaments, CEA, INRAE, Université Paris Saclay, Gif-Sur-Yvette, France.

Yasmina Adimy (Y)

Service de Pharmacologie et immunoanalyse (SPI), Laboratoire d'Etude du Métabolisme des Médicaments, CEA, INRAE, Université Paris Saclay, Gif-Sur-Yvette, France.

Martine Cohen-Solal (M)

Universite de Paris, Paris, France.
Bone and Joint Laboratory, INSERM U1132, Paris, France.

Pascal Richette (P)

Universite de Paris, Paris, France.
INSERM, UMR-S 1132, F-75010, Paris, France.

Thomas Bardin (T)

Universite de Paris, Paris, France.
INSERM, UMR-S 1132, F-75010, Paris, France.

Jean-Pierre Riveline (JP)

Universite de Paris, Paris, France.
INSERM, Immunity and Metabolism in Diabetes Laboratory, Centre de Recherche des Cordelier, Paris, France.

Nicolas Venteclef (N)

Universite de Paris, Paris, France.
INSERM, Immunity and Metabolism in Diabetes Laboratory, Centre de Recherche des Cordelier, Paris, France.

Frédéric Lioté (F)

Universite de Paris, Paris, France.
INSERM, UMR-S 1132, F-75010, Paris, France.

Laure Campillo-Gimenez (L)

Universite de Paris, Paris, France.
INSERM, UMR-S 1132, F-75010, Paris, France.

Hang-Korng Ea (HK)

Universite de Paris, Paris, France korngea@yahoo.fr.
INSERM, UMR-S 1132, F-75010, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH